Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Real-World Analysis Evaluates Inpatient Vs Outpatient CAR T-Cell Therapy Administration in MCL and FL

March 21st 2023

A real-world analysis exploring the outcomes of inpatient vs outpatient administration of CAR T-cell therapy in patients with mantle cell lymphoma and follicular lymphoma demonstrated both similarities and some differences between the 2 patient populations.

First-line ASCT Consolidation Confers Real-world Survival Benefit in Mantle Cell Lymphoma

March 20th 2023

Consolidative autologous stem cell transplant was associated with a statistically significant lower overall mortality risk and higher overall survival probability in patients with mantle cell lymphoma vs those who did not receive consolidation.

ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma

March 19th 2023

First-line consolidative autologous stem cell transplant following first complete remission, with or without maintenance rituximab, did not result in improved overall survival for patients with mantle cell lymphoma.

Dr. Mukherjee on Maintenance Rituximab in MCL

March 17th 2023

Akash Mukherjee, MD, discusses the use of post-transplant maintenance rituximab in patients with mantle cell lymphoma who have received autologous stem cell transplant and considerations for using bendamustine/rituximab or BR plus cytarabine in elderly patients who are unfit for transplant.

Dr. Epstein-Peterson on Disease Observation and TP53 Mutations in MCL

March 16th 2023

Zachary Epstein-Peterson, MD, discusses important updates in mantle cell lymphoma treatment, including the safety and feasibility of disease observation in patients with indolent MCL and the treatment of patients with TP53-mutated MCL.

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023

Nirav N. Shah, MD, explains the choice to evaluate LV20.19 CAR in MCL, key efficacy and safety data from the follow-up study of this agent, and ongoing efforts to potentially expand its use across other B-cell malignancies.

Dr. Goy on the Management of Patients With Genetic Abnormalities and Low Risk in MCL

March 14th 2023

Andre H. Goy, MD, discusses the appropriate monitoring and management of patients with mantle cell lymphoma who display genetic abnormalities but are not considered to be high risk.

Dr. Goy on Different Presentations of MCL

March 13th 2023

Andre H. Goy, MD, discusses differentiating between disease presentations in mantle cell lymphoma.

Dr. Torka on BTK Inhibitors Available for Patients With R/R MCL

March 9th 2023

Pallawi Torka, MD, discusses the BTK inhibitors available for treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Awan Discusses Distinguishes Among Available BTK Inhibitors in MCL

March 7th 2023

Farrukh Awan, MD, discusses the potential use of BTK inhibitors in the management of mantle cell leukemia.

Dr. Shah on the Safety of LV20.19 CAR T-cell Therapy in R/R MCL

March 6th 2023

Nirav N. Shah, MD, discusses the safety of the lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens, as well as future efforts from a phase 1/2 study of the product in patients with relapsed/refractory mantle cell lymphoma.

Wang Details Caveats to Standards of Care for Treating Patients With MCL

February 28th 2023

When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.

BTK Degraders and Other Targets in Mantle Cell Lymphoma

February 28th 2023

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings from the BRUIN trial, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.

The Role of Bispecific Antibodies in Mantle Cell Lymphoma

February 21st 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Treating Patients With MCL Who Progress on BTK Inhibitors

February 21st 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

Bispecific LV20.19 CAR T Cells Induce 92% CR Rate in Relapsed/Refractory Mantle Cell Lymphoma

February 17th 2023

Bispecific CAR T-cell therapy targeting both CD20 and CD19 cells induced a 90-day complete response rate of 92% in patients with relapsed/refractory mantle cell lymphoma.

Dr. Shah on LV20.19 CAR T-cell Therapy in R/R MCL

February 16th 2023

Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Dr. Dreyling on Key Safety Data from the TRIANGLE Trial in MCL

February 15th 2023

Martin Dreyling, MD, discusses the key safety data from the phase 3 TRIANGLE trial in younger patients with mantle cell lymphoma.

Brexu-cel Is Effective and Tolerable in Relapsed/Refractory Mantle Cell Lymphoma Beyond ZUMA-2 Population

February 14th 2023

Treatment with brexucabtagene autoleucel in the standard-of-care relapsed/refractory mantle cell lymphoma setting provided an efficacy and safety profile consistent with data reported in the phase 2 ZUMA-2 trial.